小児1型糖尿病におけるTouchCare Nanoの実世界評価 (NANO-KIDS)
小児および思春期の1型糖尿病患者におけるAPGOアルゴリズム搭載TouchCare Nano自動インスリン送達システムの実世界での有効性と安全性:多施設共同観察研究
The goal of this observational study is to evaluate the effectiveness and safety of the TouchCare Nano automated insulin delivery system in children and adolescents with type 1 diabetes during routine clinical care. The study includes an initial six-month period using conventional AutoMode and a planned additional six-month observational extension using the AutoMeal function in a subset of the original participants.
The main questions are:
- How do glucose levels and insulin delivery change during the first six months of TouchCare Nano use?
- How do glucose levels and insulin delivery change when participants switch from conventional AutoMode to AutoMeal?
- How often do severe hypoglycemia and diabetic ketoacidosis occur during follow-up?
In conventional AutoMode, users estimate and enter the carbohydrate content of meals to calculate meal insulin doses. With AutoMeal, users announce the type of meal-breakfast, lunch, dinner, or snack-without routinely entering carbohydrate amounts or manually selecting an insulin dose. The conventional carbohydrate-based bolus calculator remains available when needed.
Treatment decisions, including transition to AutoMeal, are made as part of routine clinical care. Researchers collect glucose sensor data, insulin delivery information, routine clinical measurements, and safety information. Assessments take place at baseline and after 1, 3, and 6 months in the initial phase. Participants who adopt AutoMeal are assessed immediately before the transition and after 3 and 6 months of AutoMeal use.
調査の概要
状態
状態
条件
条件
詳細な説明
This multicentre, prospective, observational study evaluates the real-world effectiveness and safety of the TouchCare Nano automated insulin delivery (AID) system with the APGO algorithm in young people with type 1 diabetes. The study comprises an initial six-month observation period using conventional AutoMode and a planned six-month observational extension using the AutoMeal function in a subset of the original cohort.
Participants were eligible for the initial phase if they were aged 6-18 years, had type 1 diabetes for at least six months, weighed at least 20 kg, and required a total daily insulin dose of at least 10 units, in addition to meeting the other protocol eligibility criteria. Initiation of the system and subsequent treatment decisions occurred within routine clinical care, without study-assigned treatment allocation.
Initial AutoMode phase
Participants were followed for six months after initiation of the TouchCare Nano AID system. In conventional AutoMode, the APGO algorithm automatically adjusts basal insulin delivery and administers correction boluses, while users estimate carbohydrate intake and use the integrated bolus calculator for meal boluses.
Clinical assessments were performed at baseline and after 1, 3, and 6 months. Outcomes included time in range (TIR; 70-180 mg/dL), additional continuous glucose monitoring (CGM) metrics, insulin delivery parameters, HbA1c, anthropometric measurements, and safety events.
Of the 80 participants initially enrolled, 76 completed the initial six-month observation period.
AutoMeal extension
After completing six months of conventional AutoMode use, the 76 participants were offered the opportunity to use AutoMeal during routine clinical care. Forty-eight participants adopted AutoMeal and were included in the six-month extension analysis; 28 continued using conventional AutoMode.
The AutoMeal extension was included in the original ethics committee-approved protocol and covered by the original informed consent. No separate consent process was conducted for this phase.
AutoMeal allows users to announce meals by selecting breakfast, lunch, dinner, or snack, without routinely entering carbohydrate quantities or manually selecting or confirming an insulin dose. Following meal announcement, the system automatically manages prandial insulin delivery, while automated basal modulation and correction boluses remain active. The conventional carbohydrate-based bolus calculator remains available.
Participants and caregivers received instructions to announce meals 15 minutes before food intake. They were advised to use the conventional carbohydrate-based bolus calculator when the estimated carbohydrate content of a meal differed by more than 20% from the individual's usual carbohydrate content for the corresponding meal category.
The glucose target of 110 mg/dL, active insulin time of two hours, and enabled automated correction boluses remained unchanged following transition from AutoMode to AutoMeal.
The extension baseline was the assessment at the end of the initial six-month AutoMode phase, immediately before transition to AutoMeal. Further assessments occurred after 3 and 6 months of AutoMeal use, corresponding to approximately 9 and 12 months after initial AID initiation. CGM and insulin delivery metrics were assessed using data from the 15 days preceding each extension assessment.
The primary outcome of the extension was the change in TIR (70-180 mg/dL) from the extension baseline to six months of AutoMeal use. Additional outcomes included time in tight range (70-140 mg/dL), time above and below range, mean sensor glucose, glucose standard deviation, coefficient of variation, glucose management indicator, HbA1c, and insulin delivery parameters, including total daily insulin dose, basal insulin, automated basal insulin, and automated bolus insulin.
Safety monitoring included severe hypoglycemia requiring assistance from another person and diabetic ketoacidosis throughout follow-up. Routine diabetes education and clinical care continued during both phases.
The study was conducted in accordance with the Declaration of Helsinki and approved by the relevant Ethics Committee. Written informed consent and age-appropriate assent were obtained, as applicable. Final study data collection was completed on October 15, 2026.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
-
Florence、イタリア
- Department of Diabetology and Endocrinology at the AOU Meyer IRCCS
-
-
Italy
-
Messina、Italy、イタリア
- Pediatric Diabetology Unit at the AOU "G. Martino"
-
Naples、Italy、イタリア
- Centro Regionale di Diabetologia Pediatrica- AOU Univesità degli Studi della Campania "L.Vanvitelli"
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Children and adolescents with type 1 diabetes receiving routine care at specialized pediatric diabetes centers in Italy and initiating the TouchCare Nano automated insulin delivery system on clinical indication. A subset of the original cohort continued into a planned six-month observational extension using AutoMeal after completing six months of conventional AutoMode use.
説明
Inclusion Criteria:
- Age 6 to 18 years
- Diagnosis of type 1 diabetes mellitus for ≥6 months
- Treatment with insulin therapy (multiple daily injections or continuous subcutaneous insulin infusion) for ≥6 months prior to enrolment
- Clinical indication for transition to insulin pump therapy according to routine diabetes care
- Ability of participant and family to understand and comply with study procedures
- Written informed consent from parent(s) or legal guardian(s), and assent from the participant when applicable
Exclusion Criteria:
- Diabetic ketoacidosis within the 3 months before enrollment
- Use of medications known to affect blood glucose levels
- Body weight less than 20 kilograms
- Total daily insulin dose less than 10 international units
Eligibility for the AutoMeal extension:
Participation in and completion of the initial six-month observation period using conventional AutoMode.
Voluntary adoption of the AutoMeal function within routine clinical care. The original age eligibility criterion applies to initial enrollment. Participants reaching adulthood during follow-up remained eligible to continue. The extension was covered by the original informed consent; no separate consent process was conducted.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Young people with type 1 diabetes using the TouchCare Nano system
Participants aged 6-18 years at initial enrollment with type 1 diabetes using the TouchCare Nano automated insulin delivery system as part of routine clinical care. The original cohort included 80 participants, of whom 76 completed six months of follow-up using conventional AutoMode, with carbohydrate-based meal boluses. At the end of this period, 48 participants voluntarily adopted the AutoMeal function and were followed for an additional six months. AutoMeal allows users to announce the meal type without routinely entering carbohydrate amounts or manually selecting an insulin dose. The remaining 28 participants continued using conventional AutoMode. For the AutoMeal extension, baseline was defined as the end of the initial six-month AutoMode period, immediately before transition to AutoMeal. Subsequent assessments were performed after 3 and 6 months of AutoMeal use. Treatment decisions were made within routine clinical care, without study-assigned treatment allocation. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time in Range (70-180 mg/dL) during the initial AutoMode phase
時間枠:Baseline, 1 month, 3 months, and 6 months
|
Percentage of time that continuous glucose monitoring values are between 70 and 180 mg/dL during the initial six-month period of TouchCare Nano use in conventional AutoMode. |
Baseline, 1 month, 3 months, and 6 months
|
|
Time in Range (70-180 mg/dL) during the AutoMeal extension
時間枠:Extension baseline and 3 and 6 months after transition to AutoMeal, corresponding to approximately 6, 9, and 12 months after initial TouchCare Nano initiation.
|
Percentage of time that continuous glucose monitoring values are between 70 and 180 mg/dL, assessed at the extension baseline and after three and six months of AutoMeal use. Changes from the extension baseline are evaluated at both follow-up assessments and expressed in percentage points. The extension baseline corresponds to completion of six months of conventional AutoMode use, immediately before transition to AutoMeal. Each assessment uses CGM data from the preceding 15 days. |
Extension baseline and 3 and 6 months after transition to AutoMeal, corresponding to approximately 6, 9, and 12 months after initial TouchCare Nano initiation.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time below normale glucose range (TBR)
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
TBR is the percentage of time during which glucose values measured by continuous glucose monitoring (CGM) are below 70 mg/dL |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Total daily insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Total amount of insulin administered per day, expressed in units per day (U/day), including both basal and bolus insulin delivery. |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Glycated hemoglobin (HbA1c)
時間枠:Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Glycated hemoglobin (HbA1c) reflects the average blood glucose concentration over the preceding 8-12 weeks and is expressed as percentage (%) and mmol/mol. |
Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Number of severe low blood sugar events
時間枠:Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.
|
Number of episodes of severe hypoglycaemia requiring assistance from another person to actively administer carbohydrate, glucagon, or other resuscitative actions. |
Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.
|
|
Time above glucose normal range (TAR)
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
TAR is the percentage of time during which glucose values measured by continuous glucose monitoring (CGM) exceed 180 mg/dL |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Mean sensor glucose
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Average interstitial glucose concentration measured by continuous glucose monitoring during the assessment period. |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Total daily basal insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Total daily basal insulin dose delivered by insulin pump, defined as the cumulative background insulin administered through continuous subcutaneous insulin infusion over a 24-hour period (U/day), excluding bolus insulin. |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Total daily bolus insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Total daily bolus insulin dose delivered by insulin pump, defined as the cumulative amount of corrective and meal-related insulin administered through continuous subcutaneous insulin infusion over a 24-hour period (U/day), excluding basal/background insulin |
Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Body mass index (BMI)
時間枠:Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
Body mass index is calculated as weight in kilograms divided by height in meters squared (kg/m²) and reflects overall body weight relative to height. |
Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
|
|
Number of diabetic ketoacidosis events
時間枠:Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.
|
Number of episodes of diabetic ketoacidosis defined by hyperglycaemia associated with metabolic acidosis and requiring medical evaluation or hospitalization. |
Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Angela Zanfardino, MD、University of Campania "L.Vanvitelli"
出版物と役立つリンク
一般刊行物
- Petrovski G, Campbell J, Pasha M, Day E, Hussain K, Khalifa A, van den Heuvel T. Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents With Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed Loop System: A Randomized Controlled Trial Comparing Glucose Control. Diabetes Care. 2023 Mar 1;46(3):544-550. doi: 10.2337/dc22-1692.
- Petrovski G, Campbell J, Pasha M, Hussain K, Khalifa A, Umer F, Almajaly D, Hamdar M, Heuvel TVD, Edd SN. Twelve-Month Follow-up from a Randomized Controlled Trial of Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System. Diabetes Technol Ther. 2024 Mar;26(S3):76-83. doi: 10.1089/dia.2023.0429.
- Amadou C, Melki V, Allain J, Clavel S, Gouet D, Chaillous L, Catargi B, Schaeplynck-Belicard P, Petit C, Thivolet C, Penfornis A. Performance and patients' satisfaction with the A7+TouchCare insulin patch pump system: A randomized controlled non-inferiority study. PLoS One. 2023 Aug 24;18(8):e0289684. doi: 10.1371/journal.pone.0289684. eCollection 2023.
- Marks BE, Meighan S, Zehra A, Douvas JL, Rearson A, Suresh R, Brown EA, Wolf RM. Real-World Glycemic Outcomes with Early Omnipod 5 Use in Youth with Type 1 Diabetes. Diabetes Technol Ther. 2023 Nov;25(11):782-789. doi: 10.1089/dia.2023.0337. Epub 2023 Sep 20.
- Forlenza GP, DeSalvo DJ, Aleppo G, Wilmot EG, Berget C, Huyett LM, Hadjiyianni I, Mendez JJ, Conroy LR, Ly TT, Sherr JL. Real-World Evidence of Omnipod(R) 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther. 2024 Aug;26(8):514-525. doi: 10.1089/dia.2023.0578. Epub 2024 Feb 16.
- Kim JY, Jin SM, Kang ES, Kwak SH, Yang Y, Yoo JH, Bae JH, Moon JS, Jung CH, Bae JC, Suh S, Moon SJ, Song SO, Chon S, Kim JH. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial. Diabetologia. 2024 Jul;67(7):1235-1244. doi: 10.1007/s00125-024-06155-y. Epub 2024 Apr 18.
- Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M, Freeman K, Brown A, Court R, Baldwin S, Ogunlayi F, Stinton C, Cummins E, Al-Khudairy L. Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling. Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536.
- Hughes MS, Levy CJ. The Future of Automated Insulin Delivery Systems. Endocr Pract. 2025 Sep;31(9):1162-1170. doi: 10.1016/j.eprac.2025.05.752. Epub 2025 Jun 16.
- Zanfardino A, Iafusco D, Ippolito G, Del Giudice EM, Rollato AS, Chianese A, Figuccia A, Toni S, Ferlito AG, Piccini B. Real-World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm (APGO) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study. Diabetes Obes Metab. 2026 Jul 23. doi: 10.1111/dom.71101. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 0024366/i
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。